What factors drove the changes in Organon's revenue and profit?

What were the key takeaways from Organon’s earnings call?

What is Organon's latest dividend and current dividend yield?

What does Organon do and what are its main business segments?

What is the market's earnings forecast for Organon next quarter?

What were the key takeaways from Organon's earnings call?

What is the revenue and EPS growth rate for Organon year over year?

What is Organon's gross profit margin?

- **Nexplanon Challenges**: U.S. policy-driven 50% Q3 decline, flat 2026 outlook. **Vtama Launch**: 2026 access improvements needed for growth. **Leadership Transition**: Interim CEO focus on operational stability, CEO search underway.
- **Financial Discipline**: 2025 guidance revised to $6.2B, deleveraging via Jada sale ($440M proceeds). **Biosimilars Growth**: Hadlima up 63% YoY, Tofidence launched Q3 2025.


**【Management Opening Remarks】**
- **Internal Investigation Update**: The independent investigation into Nexplanon wholesaler sales practices concluded with no material financial impact. Leadership changes include Joe Morrissey as Interim CEO and enhanced controls to prevent future issues.
- **Leadership Transition**: Carrie Cox assumes Executive Chair role; CEO search underway with focus on global pharma experience.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $1.6B, Adjusted EBITDA $518M (32.3% margin). Nexplanon U.S. down 50% YoY, international growth 7% ex-FX.
- **Full Year Guidance**: 2025 Revenue $6.2B-$6.25B (3.2% YoY decline). Vtama launch slower than expected, respiratory portfolio decline persists.

**【Q&A Highlights】**
- **CEO Search**: Emphasis on operational excellence; no strategic shift anticipated. **Nexplanon 2026 Outlook**: Flat global sales with U.S. policy headwinds offset by international growth.
- **Vtama Access**: 2026 access improvements key to growth inflection. **Respiratory Portfolio**: Long-term decline expected due to pricing, competition.


Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue $1.6B (-1% YoY) with strong biosimilar (Hadlima +68%) and Vtama (+70%) performance. Full-year guidance raised to $6.3-6.4B.
- **Profitability**: Adjusted EBITDA margin 32.4% YTD, free cash flow $525M H1. Targeting >$900M FCF and net leverage <4x by year-end.
- **Debt Reduction**: $345M debt repayment in Q2, with $475M interest expense run rate expected in 2026.
- **Vtama Momentum**: 125+ reps, DTC campaigns, and 80% addressable population coverage by Q1 2026. H2 2025 sales target $150M.
- **Nexplanon Expansion**: Global +6% H1 growth, 5-year indication launch Q4 2025. Ex-U.S. growth (+10% Q2) offsets U.S. funding headwinds.


**【CEO Summary Section】**
- **Revenue Performance**: Q2 2025 revenue was $1.6 billion (-1% YoY at constant currency), driven by growth in fertility, biosimilars, and Vtama, offsetting Atozet LOE in Europe. Full-year guidance raised by $100M midpoint to $6.3-6.4 billion.
- **Profitability**: Adjusted EBITDA of $522M (32.7% margin) in Q2, year-to-date $1B (32.4% margin). Free cash flow of $525M before one-time costs in H1, targeting >$900M for 2025.
- **Debt Reduction**: Repaid $345M in Q2, targeting net leverage <4x by year-end and 3.5x+ by end-2026.
- **Franchise Highlights**:
  - **Women's Health**: Fertility up 15% YoY, Nexplanon global +6% H1, 5-year indication FDA submission pending.
  - **General Medicines**: Biosimilars (Hadlima +68% YoY) and Vtama (+70% YoY) driving growth. Vtama on track for 80% addressable population coverage by Q1 2026.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Q2 2025 included $60M Atozet LOE, $40M pricing pressure, and $90M volume growth (fertility, biosimilars, Vtama). FX translation added $10M favorability.
- **Margins**: Adjusted gross margin 61.7% (flat YoY), OpEx down 2% YoY due to restructuring savings. Full-year EBITDA margin guidance maintained at 31-32%.
- **Cash Flow**: Free cash flow of $525M in H1, with $175M one-time costs (restructuring, Merck exits, legal settlements). Restructuring costs revised to $250-300M vs. prior $325-375M.
- **Leverage**: Net debt $5.3B as of Q2, targeting <4x by year-end. Interest expense expected to decline to $475M in 2026 post-debt repayments.

**【Q&A Key Highlights】**
- **Vtama Strategy**: 125+ reps in field, DTC/telehealth campaigns launched in Q3, pediatric expansion. H2 2025 sales target $150M, driven by access improvements (gross-to-net ratio down 10-15pp) and new launches in Canada/Japan.
- **Nexplanon Challenges**: U.S. sales impacted by federal funding uncertainty, but ex-U.S. growth (+10% Q2) and 5-year indication launch (Q4 2025) support $1B+ franchise target.
- **Tariff Risk**: EU import tariffs up to 15% would not impact 2025 margins, but 2026+ exposure could rise. Free cash flow conversion improving as one-time costs decline.
- **Pipeline Updates**: 6219 endometriosis program discontinued due to lack of efficacy. Nexplanon 5-year indication labeling expected to create barriers for generics.


Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

- **Revenue Growth Drivers**: Nexplanon (+14%), Vtama launch, and $200M annual restructuring savings.
- **Debt Reduction Focus**: Dividend reset to accelerate deleveraging to <4x net leverage by year-end.
- **Vtama Momentum**: $150M 2025 target on track with NRx/TRx growth outpacing competitors.
- **Minimal Tariff Risk**: 75% ex-U.S. revenue, 13% China, with U.S. supply from Europe mitigating exposure.
- **Cash Flow Strength**: $146M Q1 free cash flow, targeting $900M+ for 2025.
- **Strategic Flexibility**: Capital reallocation enables future M&A while maintaining financial discipline.

**【CEO Opening Remarks】**
- Q1 2025 revenue growth driven by Nexplanon (+14%), Vtama launch success, and restructuring savings of $200M annually.
- Tariff exposure minimal in 2025; 75% ex-U.S. revenue, 13% China, with most U.S. supply from Europe.
- Dividend reset to redirect $200M to debt reduction, targeting net leverage below 4x by year-end.
- Vtama on track for $150M 2025 sales, with NRx/TRx growth outpacing competitors.
- Nexplanon to surpass $1B in 2025, with 5-year indication FDA submission pending.

**【CFO Financial Review】**
- Q1 2025: $146M free cash flow (vs. $62M prior year), adjusted EBITDA margin 32% (vs. 30.5% expected).
- Operating expenses reduced by $200M through restructuring, with $130M in commercial milestones paid.
- 2025 guidance: flat constant-currency revenue, $900M+ free cash flow, 31-32% EBITDA margin.
- FX headwind reduced to $200M (300bps) due to dollar weakening, but maintained guidance for stability.

**【Q&A Key Highlights】**
- **Vtama Access & Gross-to-Net**: Strong managed care momentum, 94% U.S. birthing hospitals stocking Jada, targeting $150M sales.
- **Capital Allocation**: Debt reduction priority over M&A; share buybacks deprioritized until leverage <4x.
- **Tariff Risk**: Minimal 2025 impact; long-term manufacturing flexibility to mitigate future risks.
- **Nexplanon Patent Defense**: Confident in 2030 applicator patent; 5-year indication launch in late 2025.
- **Business Development**: Focus on accretive, success-based deals (e.g., Vtama, Tofidence) enabled by freed capital.


Organon & Co. (OGN)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: 3% CC growth in 2024, guided to flat 2025 despite $200M Atozet LOE headwind. NEXPLANON to reach $1B in 2025.
- **Margin Management**: 31%-32% EBITDA margin maintained, $200M+ savings to offset LOE. Gross margin expansion via manufacturing separation (2027+).
- **Pipeline Momentum**: VTAMA AD launch driving 51% NRx growth, OG-6219 endometriosis Phase II results expected mid-2025. Denosumab biosimilar launch late 2025.
- **Financial Discipline**: Dividend priority, 4.2x net leverage post-Dermavant, targeting mid-3x by 2026.

**【CEO Key Highlights】**
- **2024 Full Year Revenue**: $6.4 billion (+3% at constant currency), driven by NEXPLANON (+17%), Jada ($61M launched), and biosimilars (+12%).
- **2025 Guidance**: Revenue $6.125B-$6.325B (flat CC), EBITDA margin 31%-32%. $200M+ savings to offset Atozet LOE in Europe.
- **NEXPLANON Growth**: $1B+ in 2025, targeting 5-year indication approval in late 2025. No generics expected until 2030+ due to patent protections.
- **Strategic Pillars**: Base business resiliency, $200M+ cost savings, dividend priority, and pipeline execution (VTAMA, OG-6219 for endometriosis).

**【CFO Financial Breakdown】**
- **2024 Metrics**: Adjusted EBITDA $1.96B (30.6% margin ex IPR&D), free cash flow $967M, net leverage 4.2x post-Dermavant acquisition.
- **2025 Outlook**: Gross margin 60%-61%, OpEx flat YoY. $200M+ savings from restructuring and manufacturing separation (annualizing to $275M+ in 2026+).
- **Liquidity**: $1.065B adj. net income, $864M GAAP net income. 2025 interest expense $510M, tax rate 22.5%-24.5%.

**【Q&A Key Takeaways】**
- **VTAMA Launch**: Q4 2024 sales $10M (partial quarter), 2025 target $150M+ with 2/3rds in H2. NRx growth 51% vs. pre-approval baseline, outperforming competitors.
- **Biosimilars Strategy**: Denosumab launch late 2025, Perjeta EU/Latin America 2026. Focus on high-margin opportunities with strong pipeline execution.
- **Leverage Target**: 4x+ by end-2025, mid-3x by 2026. 2025 savings ($200M+) to drive long-term margin expansion (250-300bps via manufacturing separation in 2027+).

OGN

OGN fundamentals

Earnings Call

You can ask Aime